Last reviewed · How we verify
Placebo for Azithromycin
Placebo for Azithromycin is a Small molecule drug developed by Penang Hospital, Malaysia. It is currently FDA-approved for Clinical trial control for azithromycin efficacy studies.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
Azithromycin is a small molecule medication used to treat various conditions, including Bronchiolitis Obliterans, Bone Marrow Transplantation, Idiopathic Pulmonary Fibrosis, Cough, and Urethritis. In clinical trials, Azithromycin has been compared to a placebo tablet to evaluate its effectiveness in improving symptoms and lung function in patients with certain conditions.
At a glance
| Generic name | Placebo for Azithromycin |
|---|---|
| Sponsor | Penang Hospital, Malaysia |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to measure the effect of an active drug against baseline or psychological expectation. Any observed clinical benefit from a placebo is attributable to the placebo effect—a psychobiological response involving patient expectation, conditioning, and natural disease progression rather than a specific molecular mechanism.
Approved indications
- Clinical trial control for azithromycin efficacy studies
Common side effects
Key clinical trials
- Improving Care Through Azithromycin Research for Infants in Africa (PHASE3)
- A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction (PHASE3)
- Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis (PHASE3)
- Antibiotic Treatment of Recurrent Episodes of Asthma in Children (PHASE2)
- Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0 (PHASE2)
- The Impact of Shigellosis and Recommended Treatment in Children (PHASE2)
- the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis (NA)
- Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Azithromycin CI brief — competitive landscape report
- Placebo for Azithromycin updates RSS · CI watch RSS
- Penang Hospital, Malaysia portfolio CI
Frequently asked questions about Placebo for Azithromycin
What is Placebo for Azithromycin?
How does Placebo for Azithromycin work?
What is Placebo for Azithromycin used for?
Who makes Placebo for Azithromycin?
What development phase is Placebo for Azithromycin in?
Related
- Manufacturer: Penang Hospital, Malaysia — full pipeline
- Indication: Drugs for Clinical trial control for azithromycin efficacy studies
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing